Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNOF) (“Verano” or the “Company”), a leading multi-state cannabis company, today announced an exclusive partnership with Grow Sciences, a cultivator of ...

Accèdez sans limite aux 15 000 actualités du site et recevez gratuitement chaque semaine, la Newsletter Santé log avec les ...

AMSTERDAM, Netherlands, June 19, 2025 (GLOBE NEWSWIRE) -- HLTH Inc., the leading global platform for health innovation, is proud to announce the launch of HLTH.rad, a groundbreaking new event that ...

Per June 16, 2025, BlackRock, Inc. has adjusted its holding of shares to an equivalent of 23,532,753 shares, corresponding to 5.02% (previously 4.85%) of the total share capital attached to shares.

Virbac annonce la nomination de Paul Martingell en tant que directeur général du groupe Virbac à compter du 1er septembre 2025.

The CancerVax platform is designed to harness the body’s existing immunity to detect, mark, and kill cancer cells with precision. At the core of the platform are nanoparticles that operate via a ...

LONDON, June 19, 2025 (GLOBE NEWSWIRE) -- Symbiotic.blue, the UK’s newest Techbio company has launched to innovate a next-generation artificial intelligence-driven drug discovery (AIDD) platform by ...

AVMAPKI™ FAKZYNJA™ CO-PACK is approved for the treatment of adult patients with KRAS -mutated recurrent low-grade serous ovarian cancer (LGSOC) who have received prior systemic therapy. IBTROZI™ is ...

Psyence Group Inc. (CSE: PSYG) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of nature-derived psilocybin in mental health and wellbeing is pleased to announce ...

OnlineSemaglutide.org exists to make evidence‑based GLP‑1 medications simple, safe, and affordable for adults who deserve modern weight‑care options. We combine expert clinical guidance with ...

Cellectar Biosciences, Inc. (Nasdaq: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced a ...

The Company has granted the underwriters an option, exercisable within 45 days from the date of the final prospectus, to purchase up to an additional 400,000 Ordinary Shares at the public offering ...